Plaque Psoriasis Treatment Gets Even More Company
Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.
What's the Future of the 340B Program?
Drug manufacturers are rejecting the program’s blanket discounts involving contract pharmacies. A flurry of litigation has ensued.
Immune Health Supplements May Not Be What They Seem
Consumers are purchasing dietary supplements that support or boost the immune system like never before.
Examining OUD Treatment Strategies
Opioid use disorder—how can we battle the epidemic of overdoses?
News Roundup: August 15 to August 19
Your weekly roundup of the latest news from Drug Topics®.
How Supplements and Diet Can Impact Psoriasis
Examining the results of a study examining the role of supplements and diets in managing psoriasis.
Undiagnosed Diabetes May Not Be as Common as Thought
Overall numbers may be lower, but the obese, racial/ethnic minorities, and those without health care access have higher numbers of undiagnosed diabetes
Breaking: FDA Finalizes Rule Allowing OTC Access to Hearing Aids
The rule change could save money for millions.
Nearly 40% of Americans Say Inflation Has Impacted Health Care
Patients are either skipping care completely, cutting costs elsewhere, or borrowing money to pay for health care
News Roundup: August 8 to August 12
Vivjoa Approved for Recurrent Vulvovaginal Candidiasis
Oteseconazole is a treatment option for those living with a previously unmet medical need.
News Roundup: August 1 to August 5
Rate of People Without Health Insurance Hits Record Low
More people getting health coverage, but 26.4 million still don’t have it.
A New CE Session to Check Out
A new CE opportunity that's available on-demand.
Roflumilast Cream 0.3% Approved by FDA for Plaque Psoriasis
Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.
Manchin, Schumer Deal Includes Medicare Drug Price Negotiation
A joint statement from the two Democrats senators says prescription drug reform would save the federal government $288 billion over the next 10 years.
News Roundup: July 25 to July 29
July Month in Review: Top Stories on Drug Topics®
Take a look back at our most popular news from July 2022.
Fracture Risk in Older Adults Not Cut by Vitamin D Supplements
New research adds more evidence against the supplement's efficacy in preventing fractures.
Health Benefit Literacy Still a Struggle
Third annual report from Optavise demonstrates why ongoing health benefits education is critical.
The Increasingly Relevant Role of Pharmacogenomics
Pharmacogenomics looks at how genetic influences affect an individual’s response to therapeutic medications.
News Roundup: July 18 to July 22
First, Only Zonisamide Oral Suspension for Treatment of Partial Seizures Approved by FDA
The approval represents an adjunctive therapy option for adults and pediatric patients older than age 16.
Pharmacy Groups Respond to AMA Criticism on Pharmacists Prescribing Paxlovid
Groups responded quickly in defense of pharmacists’ ability to prescribe Paxlovid through Test to Treat programs.
News Roundup: July 11 to July 15
PBMs Are Starting Group Purchasing Organizations Leading to a Question of Why
The Big Three all set up group purchasing organizations recently, but some industry observers question the timing of the move and who will benefit.
News Roundup: July 1 to July 8
MS, Myasthenia Gravis Drug Clinical Trials Put On Partial Hold
Several cases of liver injury have been identified in phase 3 clinical trials of tolebrutinib.
News Roundup: June 27 to July 1
News Roundup: June 20 to June 24
